SALMONES CAMANCHAC, GIMV, Another 7 Companies Have A High Estimated Dividend Yield

(VIANEWS) – SALMONES CAMANCHAC (SACAM.OL), GIMV (GIMB.BR), SPAREBANKEN MØRE (MORG.OL) have the highest dividend yield stocks on this list.

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SALMONES CAMANCHAC (SACAM.OL)

7.87% Foward Dividend Yield

SALMONES CAMANCHAC’s last close was kr42.20, 13.88% below its 52-week high of kr49.00. Intraday change was -0.47%.

Salmones Camanchaca S.A. engages in the salmon farming business in Chile. The company offers Atlantic and Coho salmon products in various formats, such as whole, fillet, portion, and other products including bits and pieces, harasu, and scrape meat. It also exports its products. The company was incorporated in 2009 and is based in Puerto Montt, Chile. Salmones Camanchaca S.A. is a subsidiary of Compañía Pesquera Camanchaca S.A.

Earnings Per Share

As for profitability, SALMONES CAMANCHAC has a trailing twelve months EPS of kr7.54.

PE Ratio

SALMONES CAMANCHAC has a trailing twelve months price to earnings ratio of 5.65. Meaning, the purchaser of the share is investing kr5.65 for every norwegian krone of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.27%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 40.6%, now sitting on 405.81M for the twelve trailing months.

Volume

Today’s last reported volume for SALMONES CAMANCHAC is 45 which is 97.8% below its average volume of 2049.

More news about SALMONES CAMANCHAC.

2. GIMV (GIMB.BR)

5.94% Foward Dividend Yield

GIMV’s last close was €44.20, 21.49% under its 52-week high of €56.30. Intraday change was 0.34%.

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer 2020; Connected Consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer 2020, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. It mainly focuses on European market and midcap companies in Flanders and Brussels, and also invests in Kazakhstan, Benelux, Germany, France, Italy, Luxembourg, Netherlands, United Kingdom, Russia, Czech Republic, and Slovakia. Within consumer 2020, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. It invests in small and medium sized businesses primarily with headquarters in the Benelux, France, and Germany with an enterprise value of up to €125 million ($144.76 million). It seeks to invest between €3 million ($3.47 million) to €30 million ($34.74 million). Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services based companies with headquarters in Benelux, France and DACH region. It typically makes investments between €3 million ($3.47 million) to €10 million ($11.58 million) in the biopharma and medtech and between €10 million ($11.58 million) to €30 million ($34.74 million) in the health and care services. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced computation power, and components and systems for efficient use of energy, in terms of production, storage, management, use and transport sectors. It focuses on B2B products and services, based on innovation, advanced engineering, advanced manufacturing or software. It invests in companies with an enterprise value of up to €125 million ($144.76 million). It also makes flexible equity investment (equity, semi-equity, minority or majority) but always with a meaningful impact on the company and an exit trigger. It seeks to invest between €3 million ($3.47 million) to €30 million ($34.74 million). Within sustainable cities, it focuses on Products, services and infrastructure for building sustainable urban societies: Utilities and consumer goods related to energy and other (raw) materials, Waste treatment, recycling and recovery, Construction and Infrastructure, Transport and Logistics Services, and biomass, green (sustainable) chemistry, water, offshore and maritime solutions and energy efficient infrastructure. It invests through (mezzanine, equity, minority or majority) but will always strive to have a meaningful impact on the company strategy and need an exit trigger. It also invests in semiconductors, chemicals, agriculture, clean technology, electronics, water processing and purification technologies. It seeks to invest in small to medium companies with headquarters in the Benelux, France and Germany (DACH) targeting an international customer base. For fund of fund investments, it seeks to invest in Europe. It typically invests between $2.9 million and $425.439 million in companies with an enterprise value between $86.85 million and $868.55 million and sales value ranging from $6.67 million to $567.252 million. It may take a majority or a minority stake in its portfolio companies. Its investment horizon is between four and seven years. It also seeks a board seat in its portfolio companies. It invests with capital from its own balance sheet and through various funds under management. Gimv NV was founded on February 25, 1980 and is based in Antwerp, Belgium with additional offices in Paris, France; Hague, The Netherlands; Frankfurt am Main, Germany; London, United Kingdom; Prague, Czech Republic; Warsaw, Poland; and Munich, Germany.

Earnings Per Share

As for profitability, GIMV has a trailing twelve months EPS of €-1.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.65%.

Moving Average

GIMV’s value is below its 50-day moving average of €45.31 and below its 200-day moving average of €45.27.

Revenue Growth

Year-on-year quarterly revenue growth declined by 47.6%, now sitting on 222.56M for the twelve trailing months.

More news about GIMV.

3. SPAREBANKEN MØRE (MORG.OL)

5.32% Foward Dividend Yield

SPAREBANKEN MØRE’s last close was kr75.88, 14.63% below its 52-week high of kr88.88. Intraday change was 0.45%.

Sparebanken Møre, together with its subsidiaries, provides banking services for retail and corporate customers in Norway. It operates through Retail and Real Estate Brokerage segments. The company offers services in the areas of financing, deposits and other forms of investments, payment transfers, financial advisory services, asset management, insurance, and real estate brokerage. Sparebanken Møre was founded in 1843 and is headquartered in Ålesund, Norway.

Earnings Per Share

As for profitability, SPAREBANKEN MØRE has a trailing twelve months EPS of kr15.52.

PE Ratio

SPAREBANKEN MØRE has a trailing twelve months price to earnings ratio of 4.86. Meaning, the purchaser of the share is investing kr4.86 for every norwegian krone of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.71%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SPAREBANKEN MØRE’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

SPAREBANKEN MØRE’s stock is valued at kr75.50 at 17:50 EST, way below its 52-week high of kr88.88 and way above its 52-week low of kr67.98.

Volatility

SPAREBANKEN MØRE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.65%, a negative 0.12%, and a positive 1.24%.

SPAREBANKEN MØRE’s highest amplitude of average volatility was 1.25% (last week), 1.10% (last month), and 1.24% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 20.7%, now sitting on 1.84B for the twelve trailing months.

More news about SPAREBANKEN MØRE.

4. CRCAM ATL.VEND.CCI (CRAV.PA)

4.79% Foward Dividend Yield

CRCAM ATL.VEND.CCI’s last close was €89.00, 0.35% above its 52-week high of €88.69. Intraday change was 0.01%.

Caisse régionale de Crédit Agricole Mutuel Atlantique Vendée provides banking products and services in France. It offers accounts and card services; real estate loan and consumer credit products; and life insurance products. The company provides real estate investment, and stock exchange and financial investment services, as well as retirement saving solutions. It serves individuals, private banks, businesses, professionals, farmers, public community and social housing, and associations. The company was incorporated in 2001 and is headquartered in Nantes, France. Caisse régionale de Crédit Agricole Mutuel Atlantique Vendée is a subsidiary of Crédit Agricole S.A.

Earnings Per Share

As for profitability, CRCAM ATL.VEND.CCI has a trailing twelve months EPS of €18.

PE Ratio

CRCAM ATL.VEND.CCI has a trailing twelve months price to earnings ratio of 4.89. Meaning, the purchaser of the share is investing €4.89 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.74%.

Yearly Top and Bottom Value

CRCAM ATL.VEND.CCI’s stock is valued at €88.02 at 17:50 EST, below its 52-week high of €88.69 and way higher than its 52-week low of €64.16.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 12, 2023, the estimated forward annual dividend rate is 4.02 and the estimated forward annual dividend yield is 4.79%.

More news about CRCAM ATL.VEND.CCI.

5. SANOFI (SAN.PA)

3.56% Foward Dividend Yield

SANOFI’s last close was €99.40, 5.5% below its 52-week high of €105.18. Intraday change was -0.91%.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, SANOFI has a trailing twelve months EPS of €6.65.

PE Ratio

SANOFI has a trailing twelve months price to earnings ratio of 15.03. Meaning, the purchaser of the share is investing €15.03 for every euro of annual earnings.

Moving Average

SANOFI’s worth is above its 50-day moving average of €98.11 and way higher than its 200-day moving average of €88.92.

More news about SANOFI.

6. BOIRON (BOI.PA)

2.82% Foward Dividend Yield

BOIRON’s last close was €39.05, 26.6% under its 52-week high of €53.20. Intraday change was -0.38%.

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Earnings Per Share

As for profitability, BOIRON has a trailing twelve months EPS of €2.89.

PE Ratio

BOIRON has a trailing twelve months price to earnings ratio of 13.58. Meaning, the purchaser of the share is investing €13.58 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.

More news about BOIRON.

7. TECHNIP ENERGIES (TE.PA)

2.58% Foward Dividend Yield

TECHNIP ENERGIES’s last close was €19.10, 10.37% under its 52-week high of €21.31. Intraday change was 0%.

Technip Energies N.V., together with its subsidiaries, operates as an engineering and technology company for the energy transition in Europe, Russia, the Asia Pacific, Africa, the Middle East, and the Americas. The company operates in two segments, Projects Delivery; and Technology, and Products and Services. It is involved in the engineering, procurement, construction management, commissioning, and transport and installation of various energy projects. The company also engages in the study, engineering, procurement, construction, and project management of various onshore and offshore facilities related to gas monetization, ethylene, hydrogen, refining, and chemical processing from biofuels and hydrocarbons. In addition, it develops, designs, commercializes, and integrates a range of technologies in gas monetization, refining, petrochemicals and fertilizers, hydrogen, and sustainable chemistry; provides land and marine-based loading and transfer systems services to the oil and gas, petrochemical, chemical, and decarbonization industries; and offers a range of project management consulting services to the energy industry. Further, the company offers robotics, visual intelligence, and surveillance solutions, as well as nondestructive testing equipment; SnapLNG, a modularized and electrified solution; proprietary technologies relating to the design and construction of ethylene steam crackers, power generation furnace, and heat transfer equipment; engineering and technical services; and digital services. Technip Energies N.V. was incorporated in 2019 and is headquartered in Nanterre, France.

Earnings Per Share

As for profitability, TECHNIP ENERGIES has a trailing twelve months EPS of €1.68.

PE Ratio

TECHNIP ENERGIES has a trailing twelve months price to earnings ratio of 11.38. Meaning, the purchaser of the share is investing €11.38 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.38%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TECHNIP ENERGIES’s stock is considered to be overbought (>=80).

Moving Average

TECHNIP ENERGIES’s worth is higher than its 50-day moving average of €18.61 and way above its 200-day moving average of €14.49.

More news about TECHNIP ENERGIES.

8. SPIE (SPIE.PA)

2.54% Foward Dividend Yield

SPIE’s last close was €28.18, 4.28% below its 52-week high of €29.44. Intraday change was -0.07%.

SPIE SA provides multi-technical services in the areas of energy and communications. The company operates through four segments: France; Germany and Central Europe; North-Western Europe; and Oil & Gas and Nuclear. It provides technical engineering solutions for buildings; technical facility management, energy-efficiency, and technical services for the transmission and distribution of energy for industrial clients; and electrical, mechanical, and HVAC engineering services. The company also offers oil and gas services, including exploring and investigating new fields, buildings and operating facilities, and optimizing production; construction, renovation, and maintenance services for bridges, locks, and pumping stations; maintenance and innovative solutions for traffic infrastructure; and fixed and mobile digital telecom networks, as well as technical building management, communications and networks, tech FM services; engineering, construction, maintenance, and optimization services for industrial processes; energy recovery and sustainable management services to technical facilities; and energy transmission networks, medium-voltage facilities, distribution networks, busbar systems, and wind and solar power farms. In addition, it engages in the installation and maintenance of electrical systems, heating and air conditioning, building ventilation, utilities and automation for industries; and management of IT and data processing infrastructures. The company was founded in 1900 and is headquartered in Cergy-Pontoise, France.

Earnings Per Share

As for profitability, SPIE has a trailing twelve months EPS of €0.91.

PE Ratio

SPIE has a trailing twelve months price to earnings ratio of 31.16. Meaning, the purchaser of the share is investing €31.16 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.61%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SPIE’s stock is considered to be overbought (>=80).

More news about SPIE.

9. COURTOIS (COUR.PA)

2.17% Foward Dividend Yield

COURTOIS’s last close was €127.00, 5.22% under its 52-week high of €134.00. Intraday change was -1.55%.

Courtois S.A. renovates and sells real estate properties located in the Midi-Pyrenees and Paris regions in France. The company is based in Toulouse, France.

Earnings Per Share

As for profitability, COURTOIS has a trailing twelve months EPS of €12.36.

PE Ratio

COURTOIS has a trailing twelve months price to earnings ratio of 10.28. Meaning, the purchaser of the share is investing €10.28 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.66%.

Moving Average

COURTOIS’s worth is under its 50-day moving average of €127.90 and below its 200-day moving average of €128.73.

Volatility

COURTOIS’s last week, last month’s, and last quarter’s current intraday variation average was 1.20%, 0.26%, and 3.96%.

COURTOIS’s highest amplitude of average volatility was 2.00% (last week), 5.05% (last month), and 3.96% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, COURTOIS’s stock is considered to be oversold (<=20).

More news about COURTOIS.